Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study.

Abstract

The present study analysed whether autologous peripheral blood stem cell transplantation (PSCT) improves engraftment, quality of life and cost-effectiveness when compared with autologous bone marrow transplantation (ABMT). Relapsing progressive lymphoma patients (n = 204; non-Hodgkin's lymphoma n = 166; Hodgkin's disease n = 38) were, after induction treatment with the DHAP-VIM (cisplatin, cytarabine, dexamethasone, etoposide, ifosfamide, methotrexate) regimen, randomly (2:1) assigned to the harvest of granulocyte-macrophage colony-stimulating factor-mobilized stem cells after the second DHAP course or autologous bone marrow cells before the second DHAP course. These stem cells were reinfused following high-dose myeloblative chemotherapy. After induction, 118 patients obtained a partial or complete response and were eligible for randomization. In the PSCT arm (n = 76) significantly faster engraftment of neutrophils [> or = 0.1 and > or = 0.5 x 10(9)/l: 10.7 d (7-36, median, range), 15 (9-45) versus 13 (8-25) and 26 (14-80), P < 0.01] and thrombocytes [> or = 20 x 10(9)/l: 13 d (7-51) versus 18 (11-65), P < 0.01] were observed. In addition, significantly fewer transfusions of red blood cells [6 (0-23) versus 8 (2-24), P < 0.01] and platelets [4 (0-60) versus 8 (2-55), P = 0.01] were required in the PSCT arm. These findings were associated with a significant reduction in the median days of intravenous antibiotics in patients with fever [8.5 (0-30) versus 14 (0-34), P = 0.04] and hospital stay [27 (8-51) versus 34 (24-78), P < 0.05]. Quality of life demonstrated a significant difference in favour of the PSCT arm. Total transplantation costs were significantly lower in the PSCT arm [$13,954 ($4913- 29,532) versus $17 668 ($10,170-44,083) P < 0.05], as a result of the reduced hospital stay and lower antibiotic costs. In summary, these results indicate that PSCT is superior to ABMT with regard to engraftment, supportive care, quality of life and cost.

• Authors: E Vellenga, M van Agthoven, A J Croockewit, L F Verdonck, P J Wijermans, M H van Oers, C P Volkers, G W van Imhoff, T Kingma, C A Uyl-de Groot, W E Fibbe
• Journal: British journal of haematology (Br J Haematol) Vol. 114 Issue 2 Pg. 319-26 (Aug 2001) ISSN: 0007-1048 [Print] England
• PMID: 11529850 (Publication Type: Clinical Trial, Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Cytarabine
• Etoposide
• Dexamethasone
• Cisplatin
• Ifosfamide
• Methotrexate

Topics

• Adolescent
• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bone Marrow Transplantation (economics)
• Chi-Square Distribution
• Cisplatin (therapeutic use)
• Cost-Benefit Analysis
• Cytarabine (therapeutic use)
• Dexamethasone (therapeutic use)
• Disease-Free Survival
• Etoposide (therapeutic use)
• Female
• Hematopoietic Stem Cell Transplantation (economics)
• Hodgkin Disease (drug therapy, mortality, surgery)
• Humans
• Ifosfamide (therapeutic use)
• Lymphoma (drug therapy, mortality, surgery)
• Lymphoma, Non-Hodgkin (drug therapy, mortality, surgery)
• Male
• Methotrexate (therapeutic use)
• Middle Aged
• Prospective Studies
• Quality of Life
• Recurrence
• Statistics, Nonparametric
• Survival Rate
• Transplantation, Autologous